Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 71.4%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 28.6%High 0 · 0%

Dinutuximab‐containing immunotherapy vs usual care

Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
HR 0.5 [0.31, 0.8]
1 study · 226 participants
Moderate

Dinutuximab‐containing immunotherapy vs usual care

Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dinutuximab‐containing immunotherapy vs usual care

Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dinutuximab‐containing immunotherapy vs usual care

Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
HR 0.61 [0.41, 0.92]
1 study · 226 participants
Moderate

Dinutuximab‐containing immunotherapy vs usual care

Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dinutuximab‐containing immunotherapy vs usual care

Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dinutuximab‐containing immunotherapy vs usual care

Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated… 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found